Rationalisation of the differences between APOBEC3G structures from crystallography and NMR studies by molecular dynamics simulations

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Autore, Flavia ^a   Bergeron, Julien R C ^a,b   Malim, Michael H ^b   Fraternali, Franca ^a   Huthoff, Hendrik ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; VIF PROTEIN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE;

AMINO ACID SEQUENCE; ARTICLE; BETA SHEET; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DNA BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE; PROTEIN EXPRESSION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; SOLUBILITY; VIRUS INHIBITION; CHEMISTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CRYSTALLOGRAPHY; CYTIDINE DEAMINASE; HUMANS; MOLECULAR DYNAMICS SIMULATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR;

EID: 77955345928     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011515     Document Type: Article

References (55)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
2. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407.
3. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056-1060.
4. von Schwedler U, Song J, Aiken C, Trono D (1993) Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 67: 4945-4955.
5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
7. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
8. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
9. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L (2006) Inhibition of formulaprimed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 80: 11710-11722.
10. Holmes RK, Malim MH, Bishop KN (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 32: 118-128.
11. Huthoff H, Malim MH (2005) Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 334: 147-153.
12. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5: e1000330.
13. Burnett A, Spearman P (2007) APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol 81: 5000-5013.
14. Friew YN, Boyko V, Hu WS, Pathak VK (2009) Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6: 56.
15. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF (2010) A structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem 285: 16195-205.
16. Bulliard Y, Turelli P, Rohrig UF, Zoete V, Mangeat B, et al. (2009) Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J Virol 83: 12611-12621.
17. Lavens D, Peelman F, Van der Heyden J, Uyttendaele I, Catteeuw D, et al. (2010) Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res 38: 1902-1912.
18. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity. Curr Biol 15: 166-170.
19. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374-386.
20. Bishop KN, Holmes RK, Malim MH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450-8458.
21. Espinosa R, III, Funahashi T, Hadjiagapiou C, Le Beau MM, Davidson NO (1994) Assignment of the gene encoding the human apolipoprotein B mRNA editing enzyme (APOBEC1) to chromosome 12p13.1. Genomics 24: 414-415.
22. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285-296.
23. Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80: 5992-6002.
24. Chelico L, Pham P, Goodman MF (2009) Mechanisms of APOBEC3Gcatalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat Struct Mol Biol 16: 454-455.
25. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073-6076.
26. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23: 2451-2458.
27. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396.
28. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452: 116-119.
29. Holden LG, Prochnow C, Chang YP, Bransteitter R, Chelico L, et al. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456: 121-124.
30. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, et al. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J 28: 440-451.
31. Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, et al. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol 389: 819-832.
32. Shandilya SM, Nalam MN, Nalivaika EA, Gross PJ, Valesano JC, et al. (2010) Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18: 28-38.
33. Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS (2006) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 45: 447-51.
34. Bransteitter R, Prochnow C, Chen XS (2009) The current structural and functional understanding of APOBEC deaminases. Cell Mol Life Sci 66: 3137-3147.
35. Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, et al. (2007) Model structure of human APOBEC3G. PLoS One 2: e378.
36. Bennett RP, Salter JD, Liu X, Wedekind JE, Smith HC (2008) APOBEC3G Subunits Self-associate via the C-terminal Deaminase Domain. J Biol Chem 283: 33329-33336.
37. Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418: 99-103.
38. De Simone A, Dodson GG, Verma CS, Zagari A, Fraternali F (2005) Prion and water: tight and dynamical hydration sites have a key role in structural stability. Proc Natl Acad Sci U S A 102: 7535-7540.
39. Chelico L, Pham P, Calabrese P, Goodman MF (2006) APOBEC3G DNA deaminase acts processively 39 -. 59 on single-stranded DNA. Nat Struct Mol Biol 13: 392-399.
40. Nowarski R, Britan-Rosich E, Shiloach T, Kotler M (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol 15: 1059-1066.
41. Stauch B, Hofmann H, Perkovic M, Weisel M, Kopietz F, et al. (2009) Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation. Proc Natl Acad Sci U S A 106: 12079-12084.
42. Langlois MA, Beale RC, Conticello SG, Neuberger MS (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 33: 1913-1923.
43. Carpenter MA, Rajagurubandara E, Wijesinghe P, Bhagwat AS (2010) Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair 9: 579-587.
44. Bach D, Peddi S, Mangeat B, Lakkaraju A, Strub K, et al. (2008) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5: 54.
45. Berendsen HJC, van der Spoel D, van Drunen R (1995) GROMACS: A message-passing parallel molecular dynamics implementation. Comp Phys Comm 91: 43-56.
46. Daura X, Mark AE, van Gunsteren WF (1998) Parametrization of aliphatic CHn united atoms of GROMOS96 force field. J Comp Chem 19: 535-547.
47. Berendsen HJC, Postma JPM, van Gunsteren WF, Hermans J, Pullman B (1981) Interaction models for water in relation to protein hydration. Intermolecular Forces. pp 331-342.
48. Berendsen HJC, Postma JPM, van Gunsteren WF, Dinola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
49. Hess B, Bekker H, Berendsen HJC, Fraaije J (1997) LINCS: a linear constraint solver for molecular simulations. J Comp Chem 18: 1463-1472.
50. Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7: R55-R60.
51. Cavallo L, Kleinjung J, Fraternali F (2003) POPS: A fast algorithm for solvent accessible surface areas at atomic and residue level. Nucleic Acids Res 31: 3364-3366.
52. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22: 2577-2637.
53. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38.
54. Huthoff H, Malim MH (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 81: 3807-3815.
55. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH (1995) Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 69: 4166-4172.